For many years the one-size-fits-all approach has been the only one available to manage patients affected by primary biliary cholangitis. The introduction of obeticholic acid in 2016 as a second-line treatment, together with the creation and validation of several biochemically based scores to stratify the risk of progressive disease, has opened up the need to redefine clinical practice by changing the actual paradigm. The precision medicine initiative is a model of patient-centered health care that aims to improve medicine based on genotypic and molecular characteristics that correlate to specific phenotypic, individual characteristics. In summary, the aim of the precision medicine is to define the right treatment for the right person at the right time. The availability of a second-line disease-modifying drug and new molecules in phase 2 or 3 trials makes this an exciting time for the precision medicine initiative in primary biliary cholangitis. In this review we describe the current risk stratification tools and we track a possible path towards the application of precision medicine in clinical daily life.

Ronca, V., Gerussi, A., Cristoferi, L., Carbone, M., Invernizzi, P. (2019). Precision medicine in primary biliary cholangitis. JOURNAL OF DIGESTIVE DISEASES, 20(7), 338-345 [10.1111/1751-2980.12787].

Precision medicine in primary biliary cholangitis

Gerussi A.
Membro del Collaboration Group
;
Cristoferi L.
Membro del Collaboration Group
;
Carbone M.
Membro del Collaboration Group
;
Invernizzi P.
Ultimo
Membro del Collaboration Group
2019

Abstract

For many years the one-size-fits-all approach has been the only one available to manage patients affected by primary biliary cholangitis. The introduction of obeticholic acid in 2016 as a second-line treatment, together with the creation and validation of several biochemically based scores to stratify the risk of progressive disease, has opened up the need to redefine clinical practice by changing the actual paradigm. The precision medicine initiative is a model of patient-centered health care that aims to improve medicine based on genotypic and molecular characteristics that correlate to specific phenotypic, individual characteristics. In summary, the aim of the precision medicine is to define the right treatment for the right person at the right time. The availability of a second-line disease-modifying drug and new molecules in phase 2 or 3 trials makes this an exciting time for the precision medicine initiative in primary biliary cholangitis. In this review we describe the current risk stratification tools and we track a possible path towards the application of precision medicine in clinical daily life.
Articolo in rivista - Review Essay
omics; precision medicine; primary biliary cholangitis; risk stratification
English
338
345
8
Ronca, V., Gerussi, A., Cristoferi, L., Carbone, M., Invernizzi, P. (2019). Precision medicine in primary biliary cholangitis. JOURNAL OF DIGESTIVE DISEASES, 20(7), 338-345 [10.1111/1751-2980.12787].
Ronca, V; Gerussi, A; Cristoferi, L; Carbone, M; Invernizzi, P
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/240050
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
Social impact